Neoadjuvant ( n = 80) | Adjuvant ( n = 90) | P | |
---|---|---|---|
PHS (days) | 11 (7–33) | 11 (5–51) | 0.920a |
PHS with complications (days) | 15 | 17 | 0.503b |
PHS without complications (days) | 11 | 11 | 0.972a |
Patients with complications | 15 (18.8%) | 20 (22.2%) | 0.704 |
Non-surgical complications | |||
Pneumonia | 1 (1.3%) | 3 (3.3%) | 0.623 |
Pleural effusion | 0 (0.0%) | 2 (2.2%) | 0.499 |
Gastrointestinal motility disorders | 3 (3.8%) | 3 (3.3%) | 1.000 |
Thrombosis | 1 (1.3%) | 1 (1.1%) | 1.000 |
Renal dysfunction | 1 (1.3%) | 1 (1.1%) | 1.000 |
Catheter-related sepsis | 1 (1.3%) | 0 (0.0%) | 0.471 |
Other (urinary, thrombocytopenia) | 1 (1.3%) | 4 (4.4%) | 0.372 |
Surgical complications | |||
Anastomotic leakage | 0 (0.0%) | 2 (2.2%) | 0.499 |
Surgical site infection | 5 (6.2%) | 6 (6.7%) | 1.000 |
Postoperative hemorrhage | 3 (3.8%) | 1 (1.1%) | 0.343 |
Wound dehiscence | 0 (0.0%) | 2 (2.2%) | 0.499 |
Lymphorrhea | 2 (2.5%) | 1 (1.1%) | 0.602 |
Ileus | 0 (0.0%) | 1 (1.1%) | 1.000 |
Biliary fistula | 1 (1.3%) | 0 (0.0%) | 0.471 |